Transforming growth factor alpha h1
CA 2184583 A1 · Owner: The Institute For Genomic Research · Inventors: Adams, Mark D.; Fuldner, Rebecca A.; Meissner, Paul S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed is a human TGF.alpha.-H1 polypeptide and DNA (RNA) encoding such TGF.alpha.-H1 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and for producing antibodies and antagonists against such polypeptide. Such polypeptides may be combined with a suitable pharmaceutical carrier or diluent to provide diagnostic therapeutic and/or prophylactic effects against various diseases. Also provided are methods of using the antibodies and antagonists to inhibit TGF.alpha.-H1 for therapeutic purposes.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 12, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 12, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 12, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.